FDA recalls Baxter IV solutions; Drug delivery company plunges on Wall Street following bad trial results;

> Baxter ($BAX) initiated a voluntary recall of some of of its IV solutions due to the potential presence of particulate matter. More

> Alzheon believes it can succeed where many others have failed due to an oral, reformulated Alzheimer's candidate. It's a prodrug, meaning the critical ingredient is delivered in an inactive state and becomes activated once in the body. To get the treatment to Phase III, the company received $10 million in a Series A financing. The candidate will only be tested on patients with a certain gene. More

> Eye drug delivery company Ocular Therapeutix saw its stock plunge 30% last week on the heels of disappointing clinical trial results. More

Suggested Articles

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.